RESUMEN
Access to veterinary services can have positive impacts on animal health and welfare, and on human mental and physical health and well-being; however, many communities worldwide lack access to such services. At their request, the 5 communities of the Sahtu Settlement Area, Northwest Territories, Canada, have received annual access to preventive veterinary services through the University of Calgary's Northern Community Health Rotation since 2008. To determine the reach of the program, we conducted a dog census in 2017. We then conducted a chart review of 11 years of dog medical records from 2008 to 2018 to evaluate how the reach of the program, the uptake of veterinary services, and dog population demographics, health and welfare measures changed over the duration of the program. In the chart review, we used either multi-level logistic regression or generalized linear models, to determine how seven variables, including age, sex, breed, body condition, deworming, vaccination, and sterilization status upon clinic entry, changed over the course of program delivery. Our results suggest that program reach, veterinary service uptake, and dog demographic, health and welfare measures improved over time. We observed high rabies vaccination coverage in some communities (48 %-83 % of the dog population) and moderate overall sterilization status (25 %-56 % of the dog population) with female dog sterilization more common than male (75 % of dogs leaving the 2017 clinics, compared to 43 %). Several dog demographic, health, and welfare measures, including age, body condition, and vaccination, deworming, and sterilization status, were significantly better in later years of the program (all p < 0.001). Differences among communities, both in dog population numbers from the 2017 census (40-89 dogs) and in the uptake of veterinary services in 2017 (48 %-83 % of the dog population), were notable. Vaccination uptake was directly related to clinic attendance, but sterilization was impacted by additional factors, including community members' acceptance of the procedure. Some unintended consequences were noted, however, including the potential effect of sterilization on the availability of traditional dog breeds in the communities. Overall, our study findings demonstrate that subsidized veterinary services provided over a regular and extended period of time benefit animal population demographics, health and welfare, and could have positive impacts on human well-being. The framework of community collaboration and long-term commitment developed through this program serves as a model for achieving common health goals among communities in need and veterinary service providers.
Asunto(s)
Bienestar del Animal , Enfermedades de los Perros , Vacunación , Medicina Veterinaria/economía , Animales , Enfermedades de los Perros/prevención & control , Perros , Femenino , Masculino , Territorios del Noroeste , Salud Pública , Rabia/prevención & control , Rabia/veterinaria , Vacunas Antirrábicas/economía , Vacunación/economía , Vacunación/veterinariaRESUMEN
OBJECTIVE: To assess the cost and effectiveness of the two-site, 1-week, intradermal rabies post-exposure prophylaxis regimen recommended by the World Health Organization (WHO) in 2018. METHODS: We compared the number of rabies vaccine and rabies immunoglobulin ampoules consumed at The Indus Hospital in Karachi, Pakistan and their cost before and after implementing WHO's 2018 recommendations. In 2017, patients with suspected rabies-infected bites were treated using the two-site, 4-week, Thai Red Cross regimen, which involved administering four rabies vaccine doses intradermally over 4 weeks and infiltrating immunoglobulin into serious wounds, with the remainder injected into a distant muscle. In 2018, patients received three vaccine doses intradermally over 1 week, with a calculated amount of immunoglobulin infiltrated into wounds only. Remaining immunoglobulin was saved for other patients. The survival of patients bitten by apparently rabid dogs was used as a surrogate for effectiveness. FINDINGS: Despite treating 8.5% more patients in 2018 (5370 patients) than 2017 (4948 patients), 140 fewer ampoules of rabies vaccine and 436 fewer ampoules of rabies immunoglobulin were used, at a cost saving of 4202 United States dollars. Of 56 patients bitten by apparently rabid dogs, 50 were alive at 6-month follow-up. The remaining six patients could not be contacted but did not present to any hospital with rabies. CONCLUSION: The new regimen was more economical than the two-site, 4-week regimen and was equally effective. This regimen is recommended for preventing rabies in countries where the disease is endemic and rabies vaccine and immunoglobulin are in short supply.
Asunto(s)
Profilaxis Posexposición/economía , Vacunas Antirrábicas/administración & dosificación , Rabia/economía , Rabia/prevención & control , Atención Terciaria de Salud/economía , Adolescente , Animales , Mordeduras y Picaduras , Niño , Preescolar , Análisis Costo-Beneficio , Perros , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Pakistán , Profilaxis Posexposición/métodos , Vacunas Antirrábicas/economíaRESUMEN
Dog vaccination is a cost-effective approach to preventing human rabies deaths. In Haiti, the last nation-wide dog vaccination campaign occurred in 2018. We estimated the number of human lives that could be saved by resuming dog vaccination in 2021 compared to 2022 and compared the cost-effectiveness of these two scenarios. We modified a previously published rabies transmission and economic model to estimate trends in dog and human rabies cases in Haiti from 2005 to 2025, with varying assumptions about when dog vaccinations resume. We compared model outputs to surveillance data on human rabies deaths from 2005 to 2020 and animal rabies cases from 2018 to 2020. Model predictions and surveillance data both suggest a 5- to 8-fold increase in animal rabies cases occurred in Haiti's capital city between Fall 2019 and Fall 2020. Restarting dog vaccination in Haiti in 2021 compared to 2022 could save 285 human lives and prevent 6541 human rabies exposures over a five-year period. It may also decrease program costs due to reduced need for human post-exposure prophylaxis. These results show that interruptions in dog vaccination campaigns before elimination is achieved can lead to significant human rabies epidemics if not promptly resumed.
Asunto(s)
Enfermedades de los Perros/prevención & control , Vacunación Masiva/economía , Profilaxis Posexposición/economía , Vacunas Antirrábicas/economía , Rabia/prevención & control , Animales , Ciudades/epidemiología , Análisis Costo-Beneficio , Enfermedades de los Perros/epidemiología , Enfermedades de los Perros/transmisión , Enfermedades de los Perros/virología , Perros , Monitoreo Epidemiológico , Haití/epidemiología , Humanos , Vacunación Masiva/organización & administración , Modelos Económicos , Profilaxis Posexposición/organización & administración , Profilaxis Posexposición/estadística & datos numéricos , Rabia/mortalidad , Rabia/transmisión , Rabia/veterinaria , Vacunas Antirrábicas/administración & dosificaciónRESUMEN
Despite declaration as a national priority disease, dog rabies remains endemic in Liberia, with surveillance systems and disease control activities still developing. The objective of these initial efforts was to establish animal rabies diagnostics, foster collaboration between all rabies control stakeholders, and develop a short-term action plan with estimated costs for rabies control and elimination in Liberia. Four rabies diagnostic tests, the direct fluorescent antibody (DFA) test, the direct immunohistochemical test (dRIT), the reverse transcriptase polymerase chain reaction (RT-PCR) assay and the rapid immunochromatographic diagnostic test (RIDT), were implemented at the Central Veterinary Laboratory (CVL) in Monrovia between July 2017 and February 2018. Seven samples (n=7) out of eight suspected animals were confirmed positive for rabies lyssavirus, and molecular analyses revealed that all isolates belonged to the Africa 2 lineage, subgroup H. During a comprehensive in-country One Health rabies stakeholder meeting in 2018, a practical workplan, a short-term action plan and an accurately costed mass dog vaccination strategy were developed. Liberia is currently at stage 1.5/5 of the Stepwise Approach towards Rabies Elimination (SARE) tool, which corresponds with countries that are scaling up local-level interventions (e.g. dog vaccination campaigns) to the national level. Overall an estimated 5.3 - 8 million USD invested over 13 years is needed to eliminate rabies in Liberia by 2030. Liberia still has a long road to become free from dog-rabies. However, the dialogue between all relevant stakeholders took place, and disease surveillance considerably improved through implementing rabies diagnosis at the CVL. The joint efforts of diverse national and international stakeholders laid important foundations to achieve the goal of zero dog-mediated human rabies deaths by 2030.
Asunto(s)
Pruebas Diagnósticas de Rutina/veterinaria , Vacunas Antirrábicas/administración & dosificación , Rabia/diagnóstico , Rabia/prevención & control , Animales , ADN Viral , Pruebas Diagnósticas de Rutina/métodos , Enfermedades de los Perros/diagnóstico , Enfermedades de los Perros/prevención & control , Enfermedades de los Perros/virología , Perros/virología , Femenino , Humanos , Liberia/epidemiología , Masculino , Vacunación Masiva/veterinaria , Técnicas de Diagnóstico Molecular/métodos , Técnicas de Diagnóstico Molecular/veterinaria , Filogenia , Reacción en Cadena de la Polimerasa , Vacunas Antirrábicas/economía , Virus de la Rabia/genética , Virus de la Rabia/aislamiento & purificaciónRESUMEN
BackgroundThe risk of contracting rabies is low for travellers. However, the number of Dutch travellers potentially exposed abroad following an animal-associated injury and needing post-exposure prophylaxis (PEP) has increased, resulting in increased costs.AimHere, we evaluated the costs and the cost-effectiveness of different pre- and post-exposure interventions in the Netherlands, taking into account the 2018 World Health Organization (WHO) recommendations for the prevention of rabies.MethodsA decision tree-based economic model was constructed. We calculated and compared the cost of different WHO pre-exposure prophylaxis (PrEP) recommendations, intramuscular vs intradermal vaccination and PEP subsequent to increased vaccination coverage in risk groups. We estimated cost-effectiveness, expressed as incremental costs per rabies immunoglobulin (RIG) administration averted, using a societal perspective. Statistical uncertainty regarding number of travellers and vaccination coverage was assessed.ResultsTotal costs at the national level were highest using previous WHO recommendations from 2012, estimated at EUR 15.4 million annually. Intradermal vaccinations in combination with the current recommendations led to the lowest costs, estimated at EUR 10.3 million. Higher vaccination uptake resulted in higher overall costs. The incremental costs per RIG administration averted varied from EUR 21,300-46,800.ConclusionsThe change in rabies PrEP and PEP recommendations in 2018 reduced total costs. Strategies with increased pre-travel vaccination uptake led to fewer RIG administrations and fewer vaccinations after exposure but also to higher total costs. Although larger scale intradermal administration of rabies vaccine can reduce total costs of PrEP and can positively influence vaccination uptake, it remains a costly intervention.
Asunto(s)
Profilaxis Posexposición/economía , Profilaxis Pre-Exposición/economía , Vacunas Antirrábicas/administración & dosificación , Vacunas Antirrábicas/economía , Virus de la Rabia/inmunología , Rabia/prevención & control , Animales , Análisis Costo-Beneficio , Humanos , Modelos Económicos , Profilaxis Posexposición/estadística & datos numéricos , Profilaxis Pre-Exposición/estadística & datos numéricos , Rabia/inmunología , Vacunación/economía , Vacunación/métodosRESUMEN
The World Health Organization (WHO) issued an updated position paper on rabies in 2018, mainly focusing on simplification of vaccination schedules and use of rabies immunoglobulin (RIG). The maximum amount of RIG anatomically feasible should be infiltrated exclusively in and around the wound and will no longer be calculated solely based on body weight. We describe the practical guideline implementing the revised RIG policy in the Netherlands on how to determine the amount of RIG for local administration. We calculated savings achieved through the revised WHO policy. We used information from a national database including rabies consultations in the Netherlands and clinical information from a public health service, clinical practitioners and national data on the amount of distributed RIG. Between 2008 and 2019, 5,164 consultations were registered. The most frequently affected anatomical location was hand or leg (43%). Around 80% concerned minor injuries (< 2â¯cm). From January 2016 to end December 2019, 7,361 mL RIG were distributed for 1,042 possible rabies exposures (EUR 1.4 million). Since implementing the revised policy, the amount of RIG distributed per order has sharply decreased (59%). Infiltrating RIG only locally saved large quantities of human RIG (EUR 1.1 million during 4 years) in the Netherlands.
Asunto(s)
Profilaxis Posexposición/métodos , Guías de Práctica Clínica como Asunto , Vacunas Antirrábicas/administración & dosificación , Vacunas Antirrábicas/economía , Rabia/prevención & control , Administración Tópica , Animales , Análisis Costo-Beneficio , Política de Salud , Humanos , Países Bajos/epidemiología , Rabia/epidemiología , Organización Mundial de la SaludRESUMEN
OBJECTIVE: To analyze decision-making concerning stewardship and procurement mechanisms in the context of the Program for Prevention and Control of Human Rabies and the National Canine and Feline Vaccination Week in Mexico. MATERIALS AND METHODS: The information was obtained through requests to the National Institute of Transparency, Access to Information and Protection of Personal Data. RESULTS: From 2009 to 2017, 158.9 million doses of canine rabies vaccine (VAR-CF) were applied with an estimated budget of 1 915 million pesos. Our findings suggest weak stewardship and ineffective governance that allows monopolistic practices and fragmented and direct purchases. Prices for the same product vary discretionally between states and are significantly higher than those offered at international level. CONCLUSIONS: After 30 years of operation of the SNVA-C in Mexico, high prices of the VAR-CF persist, which are indicative of a significant market failure, characterized by zero competition, asymmetric information and misaligned incentive structures that precluded favorable price negotiation.
OBJETIVO: Analizar la rectoría y los mecanismos de procuración de insumos en el contexto del Programa de Acción Específico de Prevención y Control de la Rabia Humana y la Semana Nacional de Vacunación Antirrábica canina y felina en México (SNVA-C). MATERIAL Y MÉTODOS: La información se obtuvo mediante solicitudes al Instituto Nacional de Transparencia, Acceso a la Información y Protección de Datos Personales. RESULTADOS: De 2009 a 2017 se aplicaron 158.9 millones de dosis de vacuna antirrábica canina y felina (VAR-CF) por un monto de compra aproximado de 1 915 MDP. Se documentó una débil rectoría que permite prácticas monopólicas y compras fragmentadas y directas. Las adquisiciones se han fincado con precios que varían entre entidades federativas y son significativamente más altos que los precios internacionales. CONCLUSIONES: Después de 30 años de operación de la SNVA-C en México, persisten pagos excesivos para la VAR-CF, los cuales son indicativos de una falla importante del mercado, caracterizada por nula competencia, información asimétrica y estructuras de incentivos desalineadas que impiden obtener un precio competitivo.
Asunto(s)
Enfermedades de los Gatos/prevención & control , Enfermedades de los Perros/prevención & control , Vacunas Antirrábicas/administración & dosificación , Rabia/veterinaria , Vacunación/veterinaria , Animales , Gatos , Perros , Competencia Económica , México , Rabia/prevención & control , Vacunas Antirrábicas/economía , Vacunación/economía , Vacunación/estadística & datos numéricosRESUMEN
Resume: Objetivo: Analizar la rectoría y los mecanismos de procuración de insumos en el contexto del Programa de Acción Específico de Prevención y Control de la Rabia Humana y la Semana Nacional de Vacunación Antirrábica canina y felina en México (SNVA-C). Material y métodos: La información se obtuvo mediante solicitudes al Instituto Nacional de Transparencia, Acceso a la Información y Protección de Datos Personales. Resultados: De 2009 a 2017 se aplicaron 158.9 millones de dosis de vacuna antirrábica canina y felina (VAR-CF) por un monto de compra aproximado de 1 915 MDP. Se documentó una débil rectoría que permite prácticas monopólicas y compras fragmentadas y directas. Las adquisiciones se han fincado con precios que varían entre entidades federativas y son significativamente más altos que los precios internacionales. Conclusión: Después de 30 años de operación de la SNVA-C en México, persisten pagos excesivos para la VAR-CF, los cuales son indicativos de una falla importante del mercado, caracterizada por nula competencia, información asimétrica y estructuras de incentivos desalineadas que impiden obtener un precio competitivo.
Abstract: Objective: To analyze decision-making concerning stewardship and procurement mechanisms in the context of the Program for Prevention and Control of Human Rabies and the National Canine and Feline Vaccination Week in Mexico. Materials and methods: The information was obtained through requests to the National Institute of Transparency, Access to Information and Protection of Personal Data. Results: From 2009 to 2017, 158.9 million doses of canine rabies vaccine (VAR-CF) were applied with an estimated budget of 1 915 million pesos. Our findings suggest weak stewardship and ineffective governance that allows monopolistic practices and fragmented and direct purchases. Prices for the same product vary discretionally between states and are significantly higher than those offered at international level. Conclusions: After 30 years of operation of the SNVA-C in Mexico, high prices of the VAR-CF persist, which are indicative of a significant market failure, characterized by zero competition, asymmetric information and misaligned incentive structures that precluded favorable price negotiation.
Asunto(s)
Animales , Gatos , Perros , Rabia/veterinaria , Vacunas Antirrábicas/administración & dosificación , Enfermedades de los Gatos/prevención & control , Vacunación/veterinaria , Enfermedades de los Perros/prevención & control , Rabia/prevención & control , Vacunas Antirrábicas/economía , Vacunación/economía , Vacunación/estadística & datos numéricos , Competencia Económica , MéxicoRESUMEN
OBJECTIVES: Once symptoms appear, rabies is almost always fatal and accounts for 200-300 deaths annually in the Philippines. Available rabies vaccines can be administered either in pre- exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP). After exposure, PrEP-immunized individuals require fewer doses of PEP and no rabies immunoglobulin. METHODS: A static decision-tree model was developed to assess cost-effectiveness of a PrEP+PEP program vs PEP alone. Philippines-specific data for people seeking medical advice at the Research Institute for Tropical Medicine between July 2015 and June 2016 were used in the model, together with data from published literature. RESULTS: Over a 20-year period, in a cohort of 1 million 5-year-old children in the Philippines, PrEP+PEP was expected to prevent 297 deaths compared with PEP alone. From both payer and societal perspectives, the resulting incremental cost-effectiveness ratios were 36 035 (US$759; 2016 US$ conversion) and 18 663 (US$393) Philippine Pesos (PHP) - quality-adjusted life-years gained - respectively, which are both below the willingness-to-pay threshold of PHP140 255 (US$2 953). CONCLUSION: These data suggest that a universal PrEP program targeting 5-year-olds would be cost-effective in the Philippines.
Asunto(s)
Profilaxis Posexposición/economía , Profilaxis Pre-Exposición/economía , Vacunas Antirrábicas/economía , Rabia/prevención & control , Preescolar , Estudios de Cohortes , Análisis Costo-Beneficio , Humanos , Filipinas , Años de Vida Ajustados por Calidad de Vida , Rabia/economía , Rabia/mortalidadRESUMEN
Rabies is the most dreaded neglected zoonosis worldwide. It affects mostly developing countries with limited access to post-exposure prophylaxis and a low coverage of dog vaccination. OBJECTIVE: This study estimates the burden of human rabies in Mali from the extrapolation of animal bite surveillance, mostly dogs, in the region of Sikasso and the District of Bamako in 2016 and 2017. MATERIAL AND METHODS: Monte Carlo simulations of a series of interconnected probabilities were used to estimate the burden of rabies. The data was collected from cross-sectional surveys of 8775 households of which 4172 were in the District of Bamako and 4603 in the region of Sikasso. Further data was collected in health centres and from the respective veterinary services. RESULTS: We estimate that in the year 2016 133 [95% Confidence Interval (95%CI) 87-186] people died and that 5'366 [95%CI 3'510-7'504] years of life (YLL) were lost and in 2017 et 136 [95%CI 96-181] people died and that 5530 [IC 95% 3'913-7'377] YLLs were lost. The loss of income was estimated at 3.2 million USD [95%CI 2,1-4,5] en 2016, and 3,3 million USD [95%CI 2,3-4,4] in 2017. This represents the highest financial loss from rabies, followed by the cost of postexposure prophylaxis (PEP) of 86'848 $USD and 89'371 $ USD respectively. From the whole cost of rabies in Mali, 92% of the cost in 2016 and 94% of those in 2017 were attributable to premature mortality and the cost of help seeking. The proportion of cost of PEP was 3% in 2016 and 2017 of the total cost of disease. The cost related to dog vaccination changed from 3% to 1% in the same time period. CONCLUSION: This study shows that despite the possibility of preventing human rabies by PEP, its burden remains important in Malian communities. Rabies control by mass vaccination of dogs is hardly done and access to PEP is difficult. However, Rabies elimination by mass vaccination of dogs has been demonstrated to be feasible. Hence a coordinated regional effort between countries by funding dog mass vaccination and full access to PEP can eliminate rabies in West Africa.
Asunto(s)
Rabia/economía , Rabia/epidemiología , Animales , Costo de Enfermedad , Estudios Transversales , Enfermedades de los Perros/epidemiología , Perros , Humanos , Malí , Vacunación Masiva/veterinaria , Modelos Econométricos , Método de Montecarlo , Profilaxis Posexposición/economía , Profilaxis Posexposición/métodos , Vacunas Antirrábicas/administración & dosificación , Vacunas Antirrábicas/economíaRESUMEN
OBJECTIVES: Hoping to improve health-related effectiveness, a two-phase vaccination against rabies was designed and executed in northern Tanzania in 2018, which included geo-epidemiological and economic perspectives. METHODS: Considering the local bio-geography and attempting to rapidly establish a protective ring around a city at risk, the first phase intervened on sites surrounding that city, where the population density was lower than in the city at risk. The second phase vaccinated a rural area. RESULTS: No rabies-related case has been reported in the vaccinated areas for over a year post-immunisation; hence, the campaign is viewed as highly cost-effective. Other metrics included: rapid implementation (concluded in half the time spent on other campaigns) and the estimated cost per protected life, which was 3.28 times lower than in similar vaccinations. CONCLUSIONS: The adopted design emphasised local bio-geographical dynamics: it prevented the occurrence of an epidemic in a city with a higher demographic density than its surrounding area and it also achieved greater effectiveness than average interventions. These interdisciplinary, policy-oriented experiences have broad and immediate applications in settings of limited and/or time-sensitive (expertise, personnel, and time available to intervene) resources and conditions.
Asunto(s)
Programas de Inmunización , Vacunas Antirrábicas/administración & dosificación , Rabia/prevención & control , Animales , Enfermedades de los Gatos/prevención & control , Gatos , Análisis Costo-Beneficio , Enfermedades de los Perros/prevención & control , Perros , Femenino , Humanos , Programas de Inmunización/economía , Rabia/economía , Rabia/transmisión , Vacunas Antirrábicas/economía , TanzaníaRESUMEN
BACKGROUND: Achieving the Sustainable Development Goal of a 90% reduction in neglected tropical diseases (NTDs) by 2030 requires innovative control strategies. This proof-of-concept study examined the effectiveness of integrating control programs for two NTDs: mass drug administration (MDA) for soil-transmitted helminths in humans and mass dog rabies vaccination (MDRV). METHODS: The study was carried out in 24 Tanzanian villages. The primary goal was to demonstrate the feasibility of integrating community-wide MDA for STH and MDRV for rabies. The objectives were to investigate the popularity, participation and cost and time savings of integrated delivery, and to investigate the reach of the MDA with respect to primary school-aged children and other community members. To implement, we randomly allocated villages for delivery of MDA and MDRV (Arm A), MDA only (Arm B) or MDRV only (Arm C). RESULTS: Community support for the integrated delivery was strong (e.g. 85% of focus group discussions concluded that it would result in people getting "two for one" health treatments). A high proportion of households participated in the integrated Arm A events (81.7% MDA, 80.4% MDRV), and these proportions were similar to those in Arms B and C. These findings suggest that coverage might not be reduced when interventions are integrated. Moreover, in addition to time savings, integrated delivery resulted in a 33% lower cost per deworming dose and a 16% lower cost per rabies vaccination. The median percentage of enrolled primary school children treated by this study was 76%. However, because 37% of the primary school aged children that received deworming treatment were not enrolled in school, we hypothesize that the employed strategy could reach more school-aged children than would be reached through a solely school-based delivery strategy. CONCLUSIONS: Integrated delivery platforms for health interventions can be feasible, popular, cost and time saving. The insights gained could be applicable in areas of sub-Saharan Africa that are remote or underserved by health services. These results indicate the utility of integrated One Health delivery platforms and suggest an important role in the global campaign to reduce the burden of NTDs, especially in hard-to-reach communities. TRIAL REGISTRATION: clinicaltrials.gov NCT03667079 , retrospectively registered 11th September 2018.
Asunto(s)
Prestación Integrada de Atención de Salud , Enfermedades de los Perros/prevención & control , Helmintiasis/prevención & control , Rabia/prevención & control , Suelo/parasitología , Animales , Niño , Ahorro de Costo/estadística & datos numéricos , Prestación Integrada de Atención de Salud/economía , Perros , Helmintiasis/transmisión , Humanos , Administración Masiva de Medicamentos/economía , Vacunación Masiva/economía , Vacunación Masiva/veterinaria , Evaluación de Programas y Proyectos de Salud , Rabia/transmisión , Rabia/veterinaria , Vacunas Antirrábicas/administración & dosificación , Vacunas Antirrábicas/economía , Población Rural , Tanzanía/epidemiologíaRESUMEN
The expenditure for rabies postexposure prophylaxis (PEP) is substantial, especially for the poor who are affected the most. The present study was conducted to determine the cost incurred to a patient and the healthcare facility for providing PEP in different healthcare settings. A multicentric, health facility-based study was conducted from May 2017 to January 2018 in the six states involving 18 healthcare facilities. The study included 529 animal bite cases; most of them belonged to either category III (54.4%) or category II (43.1%) exposures and all of them received complete PEP. The total median cost incurred to the patients for complete PEP in the government health facility was INR 1400 (USD 22) and in private hospitals was INR 3685 (USD 58). The cost of PEP for the bite victims is considerable; therefore, it has to be provided free of charge at all healthcare facilities.
Asunto(s)
Profilaxis Posexposición/economía , Vacunas Antirrábicas/administración & dosificación , Vacunas Antirrábicas/economía , Rabia/prevención & control , Mordeduras y Picaduras/epidemiología , Gastos en Salud/estadística & datos numéricos , Humanos , India/epidemiología , Profilaxis Posexposición/métodos , Sector Privado/economía , Sector Público/economía , Rabia/epidemiologíaRESUMEN
BACKGROUND: Rabies is a neglected zoonotic disease with a global burden of approximately 59,000 human deaths a year. Once clinical symptoms appear, rabies is almost invariably fatal; however, with timely and appropriate post-exposure prophylaxis (PEP) consisting of wound washing, vaccine, and in some cases rabies immunoglobulin (RIG), the disease is almost entirely preventable. Access to PEP is limited in many countries, and when available, is often very expensive. METHODS: We distributed a standardized assessment tool electronically to a convenience sample of 25 low- and middle-income countries in Asia and Africa to collect information on rabies PEP procurement, forecasting, distribution, monitoring and reporting. Information was collected from national rabies focal points, focal points at the World Health Organization (WHO) country offices, and others involved in procurement, logistics and distribution of PEP. Because RIG was limited in availability or unavailable in many countries, the assessment focused on vaccine. Data were collected between January 2017 and May 2018. RESULTS: We received responses from key informants in 23 countries: 11 countries in Asia and 12 countries in Africa. In 9 of 23 (39%) countries, rabies vaccine was provided for free in the public sector and was consistently available. In 10 (43%) countries, all or some patients were required to pay for the vaccine in the public sector, with the cost of a single dose ranging from US$ 6.60 to US$ 20/dose. The primary reason for the high cost of the vaccine for patients was a lack of funding at the central level to subsidize vaccine costs. In the remaining 4 (17%) countries, vaccine was provided for free but was often unavailable so patients were required to purchase it instead. The majority of countries used the intramuscular route for vaccine administration and only 5 countries exclusively used the dose-sparing intradermal (ID) route. Half (11/22; 50%) of all countries assessed had a standardized distribution system for PEP, separate from the systems used for routine childhood vaccines, and almost half used separate storage facilities at both central and health facility levels. Approximately half (9/22; 41%) of all countries assessed reported having regular weekly, monthly or quarterly reporting on rabies vaccination. CONCLUSIONS: While all countries in our assessment had rabies vaccines available in the public sector to some extent, barriers to access include the high cost of the vaccine to the government as well as to patients. Countries should be encouraged to use ID administration as this would provide access to rabies vaccine for many more people with the same number of vaccine vials. In addition, standardized monitoring and reporting of vaccine utilization should be encouraged, in order to improve data on PEP needs.
Asunto(s)
Accesibilidad a los Servicios de Salud , Factores Inmunológicos/provisión & distribución , Profilaxis Posexposición/métodos , Profilaxis Posexposición/provisión & distribución , Vacunas Antirrábicas/provisión & distribución , Rabia/prevención & control , África , Asia , Humanos , Factores Inmunológicos/administración & dosificación , Factores Inmunológicos/economía , Profilaxis Posexposición/economía , Sector Público , Vacunas Antirrábicas/administración & dosificación , Vacunas Antirrábicas/economíaRESUMEN
Objective: To evaluate the cost-utility of different immunization strategies for rabies in China, and to provide a reference for determining the optimal immunization strategy. Methods: The system dynamics model was used to simulate the epidemic of canine rabies and a decision tree model was conducted to analysis different immune strategies. Relevant probabilities were obtained through literature search and on-site investigation. Sensitivity analysis was used to explore the important influenced factors. Results: At baseline, from a social perspective, 70% vaccination of dogs was the optimal strategy compared to current vaccination strategy (43% vaccination in dogs, human category-â ¡ exposure vaccination/category-â ¢ exposure vaccination combined with RIG). The total cost was 14 084 354 CNY, and the total utility value was 22 078 616.23 QALYs, and the incremental cost-utility ratio was-62 148 147 CNY/QALY; if human vaccination was considered, 55% vaccination of dogs combined with strategy one was the optimal strategy, its incremental cost-utility ratio was-444 620 557 CNY/QALY. The probability that an injured dog carries rabies virus was the most sensitive parameter. When it was greater than 0.005 03, strategy four was the optimal strategy. When it was less than 82/100 000, strategy one was the optimal strategy; when it was between 82/100 000 and 120/100 000, strategy two was the optimal strategy; when it was between 120/100 000 and 503/100 000, strategy two was the optimal strategy. Conclusion: It was conducive to increase the vaccination coverage of canine for the prevention and control of rabies.
Asunto(s)
Análisis Costo-Beneficio , Vacunas Antirrábicas/uso terapéutico , Rabia/prevención & control , Animales , China , Árboles de Decisión , Perros , Humanos , Años de Vida Ajustados por Calidad de Vida , Rabia/economía , Vacunas Antirrábicas/economía , VacunaciónAsunto(s)
Vacunas Antirrábicas/economía , Vacunación/economía , Vacunación/ética , Animales , China , Humanos , Rabia/prevención & controlRESUMEN
BACKGROUND: Rabies remains a major public health problem in developing countries. Most fatal rabies cases, especially in children, result from dog bites and occur in low-income countries, such as those in Sub-Saharan Africa. Rabies can be controlled through mass dog vaccination and human deaths prevented through timely and appropriate post-exposure prophylaxis (PEP). As access to appropriate PEP remains a serious challenge for bite-victims, the aim of this study was to understand the use of PEP, to evaluate the knowledge, attitudes and practices with respect to rabies and to identify risk factors related to non-compliance with PEP to define recommendations for improving PEP in Senegal. METHODS: This study included patients with suspicion of rabies exposure who sought PEP at the Pasteur Institute of Dakar from April 2013 to March 2014. Patients with rabies clinical symptoms, those who had already started PEP and those with exposure outside Senegal or for more than 3 months were excluded. Data on risk factors and propensity to seek and complete PEP were collected using questionnaires and phone interviews. The association between acceptability and compliance with PEP and other independent variables were evaluated using multivariate regression analysis. RESULTS: Among the 905 patients enrolled into the study, 67% were male (sex ratio M/F, 2) and 46%, children under 15 years of age. Exposures by animal bites represented 87%, whereas the remainder were due to scratches or contact; 76% were classified as WHO category III and 88% were due to dogs. Among these patients, 7% refused to start PEP and 54.5% completed the full schedule. Main factors reported by non-compliant patients were vaccine costs and affordability, and knowledge on status of biting animal. CONCLUSION: This study shows that despite the awareness about rabies dangers and prevention, only half of the patients completed the full PEP schedule. The following recommendations, such as free of charge prophylaxis or intradermal regimens as an alternative to intramuscular regimens, should be considered to increase the adherence to PEP at the Pasteur Institute of Dakar and in Senegal.
Asunto(s)
Conocimientos, Actitudes y Práctica en Salud , Profilaxis Posexposición , Vacunas Antirrábicas/uso terapéutico , Rabia/prevención & control , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Animales , Mordeduras y Picaduras , Niño , Preescolar , Estudios de Cohortes , Costos y Análisis de Costo , Países en Desarrollo , Femenino , Humanos , Lactante , Masculino , Persona de Mediana Edad , Cooperación del Paciente , Profilaxis Posexposición/métodos , Profilaxis Posexposición/tendencias , Estudios Prospectivos , Vacunas Antirrábicas/economía , Factores de Riesgo , Senegal , Adulto JovenRESUMEN
BACKGROUND: Tens of thousands of people die from dog-mediated rabies annually. Deaths can be prevented through post-exposure prophylaxis for people who have been bitten, and the disease eliminated through dog vaccination. Current post-exposure prophylaxis use saves many lives, but availability remains poor in many rabies-endemic countries due to high costs, poor access, and supply. METHODS: We developed epidemiological and economic models to investigate the effect of an investment in post-exposure prophylaxis by Gavi, the Vaccine Alliance. We modelled post-exposure prophylaxis use according to the status quo, with improved access using WHO-recommended intradermal vaccination, with and without rabies immunoglobulin, and with and without dog vaccination. We took the health provider perspective, including only direct costs. FINDINGS: We predict more than 1 million deaths will occur in the 67 rabies-endemic countries considered from 2020 to 2035, under the status quo. Current post-exposure prophylaxis use prevents approximately 56â000 deaths annually. Expanded access to, and free provision of, post-exposure prophylaxis would prevent an additional 489â000 deaths between 2020 and 2035. Under this switch to efficient intradermal post-exposure prophylaxis regimens, total projected vaccine needs remain similar (about 73 million vials) yet 17·4 million more people are vaccinated, making this an extremely cost-effective method, with costs of US$635 per death averted and $33 per disability-adjusted life-years averted. Scaling up dog vaccination programmes could eliminate dog-mediated rabies over this time period; improved post-exposure prophylaxis access remains cost-effective under this scenario, especially in combination with patient risk assessments to reduce unnecessary post-exposure prophylaxis use. INTERPRETATION: Investing in post-exposure vaccines would be an extremely cost-effective intervention that could substantially reduce disease burden and catalyse dog vaccination efforts to eliminate dog-mediated rabies. FUNDING: World Health Organization.
Asunto(s)
Enfermedades de los Perros/prevención & control , Profilaxis Posexposición/economía , Vacunas Antirrábicas/economía , Virus de la Rabia/inmunología , Rabia/epidemiología , Rabia/prevención & control , Vacunación/economía , Animales , Mordeduras y Picaduras/virología , Preescolar , Análisis Costo-Beneficio/métodos , Perros , Enfermedades Endémicas/prevención & control , Femenino , Humanos , Inmunoglobulinas/uso terapéutico , Incidencia , Masculino , Modelos Económicos , Profilaxis Posexposición/métodos , Años de Vida Ajustados por Calidad de Vida , Rabia/mortalidad , Rabia/virología , Vacunas Antirrábicas/uso terapéutico , Virus de la Rabia/aislamiento & purificación , Organización Mundial de la SaludRESUMEN
The public health and economic burden of rabies has led to major intersectoral initiatives worldwide to reduce its burden. Over the last decade, the impact of rabies prevention and control programmes in real-world settings has become increasingly evident, especially in countries where most rabies exposures and deaths occur, but they have yet to successfully eradicate rabies due to limited access to health care services. We aimed to systematically review published transmission dynamic modelling studies of rabies in both humans and dogs with a focus on studies which estimated the epidemiological and economic impact of different preventive measures. The findings are intended to inform the World Health Organization's (WHO) Strategic Advisory Group of Experts on Immunization (SAGE) to improve programmatic feasibility and clinical practice in rabies. Medline and Scopus were systematically searched for peer-reviewed articles which were published up to 14th June 2017. In addition, studies identified from a meeting of the WHO Expert Consultation on Rabies on 26-28th April 2017 in Bangkok, Thailand were added, resulting in 19 articles which were included in the review. Results from the disease modelling indicated that the basic reproduction number was low (less than 2 in all but one study). All studies found that rabies control through canine vaccination was likely to be effective in terms of reducing the incidence of rabies in dogs and/or humans, with most studies suggesting 70% annual coverage was adequate. Vaccine coverage, dog density and birth rate were identified as crucial factors influencing the effectiveness of the interventions. In conclusion, the findings from this review suggest that rabies control through canine vaccination is likely to be effective in reducing the incidence of rabies. Vaccine coverage, dog density and canine birth rate were identified as critical factors influencing the effectiveness of vaccination interventions.